Table 3.
Patient demographics and baseline characteristics in AFM11-102
| Safety population (n = 17) |
|
|---|---|
| Age (y), mean (SD) | 46.8 (18.80) |
| Male, n (%) | 7 (41.2) |
| Type of ALL, n (%) | |
| CD19 + B-precursor Philadelphia-chromosome negative ALL | 16 (94.1) |
| CD19 + B-precursor Philadelphia-chromosome positive ALL | 1 (5.9) |
| Time since diagnosis (y), mean (SD) | 1.62 (1.11) |
| Total number of relapses, mean (SD) | 1.6 (0.70) |
| Previous treatments, n (%) | |
| Chemotherapy | 17 (100) |
| Targeted therapya | 3 (17.6) |
| Radiotherapy | 3 (17.6) |
| Peripheral blood stem cell transplant | 5 (29.4) |
| Time from last treatment, n (%) | |
| < 1 month | 6 (35.3) |
| 1 to < 3 months | 4 (23.5) |
| 3 to < 6 months | 1 (5.9) |
| 6 to < 12 months | 2 (11.8) |
| ≥ 12 months | 4 (23.5) |
ALL acute lymphoblastic leukaemia; SD standard deviation
aTargeted therapy included velcade asparaginase, imatinib ponatinib or rituximab